MedTrace Logo

An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advance Refractory Cancer

NCT01443390 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2014-05-14

No results posted yet for this study

Summary

When a patient with advanced cancer consults with a member of the Phase I drug development team, the investigators utilize all information possible to try to select a therapy for that patient which has the best chance of working for them. This information includes:

1. Past published information
2. Clinical experience and judgement
3. Immunohistochemistry for specific targets (e.g., ER)
4. Standard sequencing (e.g., for K-Ras) and other methods now available.

The investigators have a new tool which warrants early exploration for what role it might eventually play in the process of selecting the best therapy for an individual patient. The basis of the current ancillary exploratory study is to gain initial experience with the operational aspects of this whole genome sequencing in this setting.

Conditions

Sponsors & Collaborators

  • National Foundation for Cancer Research

    collaborator OTHER

  • Translational Genomics Research Institute

    collaborator OTHER

  • Scottsdale Healthcare

    lead OTHER

Principal Investigators

  • Glen J Weiss, M.D. · Scottsdale Healthcare

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01443390 on ClinicalTrials.gov